Carmustine and Pulmonary toxicity - a phase IV clinical study of FDA data

Summary:

Pulmonary toxicity is reported as a side effect among people who take Carmustine (carmustine), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Etoposide, and have Non-hodgkin's lymphoma.

The phase IV clinical study analyzes which people have Pulmonary toxicity when taking Carmustine. It is created by eHealthMe based on reports of 4,562 people who have side effects when taking Carmustine from the FDA, and is updated regularly.

What is Carmustine?

Carmustine has active ingredients of carmustine. eHealthMe is studying from 4,562 Carmustine users. Check the latest studies of Carmustine.

What is Pulmonary toxicity?

Pulmonary toxicity (side effects on the lungs) is found to be associated with 374 drugs and 465 conditions by eHealthMe. Check the latest studies of Pulmonary toxicity.

On Jul, 12, 2026

4,562 people reported to have side effects when taking Carmustine.
Among them, 50 people (1.1%) have Pulmonary toxicity.

Could Carmustine cause Pulmonary toxicity?

Among these 50 people:

How long have people been on Carmustine when they have Pulmonary toxicity? *

What is the gender of people who have Pulmonary toxicity when taking Carmustine? *

female: 25.93 %
male: 74.07 %

What is the age of people who have Pulmonary toxicity when taking Carmustine? *

What are other drugs people take besides Carmustine? *

What are other side effects people have besides Pulmonary toxicity? *

Infection: 10 people, 20.00%
Cardiotoxicity (damage to the heart muscle): 10 people, 20.00%
Thrombocytopenia (decrease of platelets in blood): 8 people, 16.00%
Hepatotoxicity (chemical-driven liver damage): 6 people, 12.00%
Mucosal Inflammation (infection of mucous membrane): 6 people, 12.00%
Nephropathy Toxic (damage to kidney due to toxins): 6 people, 12.00%
Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system): 6 people, 12.00%
Organising Pneumonia (pathologically by the presence in the distal air spaces of buds of granulation tissue): 6 people, 12.00%
Pneumonia: 5 people, 10.00%
Anaemia (lack of blood): 5 people, 10.00%

What are the existing conditions these people have? *

Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 11 people, 22.00%
Bone Marrow Conditioning Regimen: 7 people, 14.00%
Peripheral T-Cell Lymphoma Unspecified Stage Iv (peripheral t-cell cancer unspecified stage iv): 6 people, 12.00%
Lymphoma (cancer that begins in immune system cells): 3 people, 6.00%
Breast Cancer: 2 people, 4.00%
Brain Stem Glioma (cancerous glioma tumour in the brainstem): 2 people, 4.00%
T-Cell Lymphoma (a blood cell cancer): 1 person, 2.00%
Multiple Myeloma (cancer of the plasma cells): 1 person, 2.00%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 1 person, 2.00%
Inflammatory Carcinoma Of The Breast: 1 person, 2.00%

* Approximation only. Some reports may have incomplete information.

Do you take Carmustine and have Pulmonary toxicity?

- Check whether Pulmonary toxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Carmustine:

Carmustine (4,562 reports)

Browse all side effects of Carmustine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulmonary toxicity:

Pulmonary toxicity (374 drugs)

Browse all the conditions that are associated with Pulmonary toxicity:

Pulmonary toxicity (465 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on carmustine (the active ingredients of Carmustine) and Carmustine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.